Regeneron Pharmaceuticals (REGN) Stock Price
Regeneron Pharmaceuticals Price
Over the last 19 years Regeneron Pharmaceuticals grew revenue by 33.0% annually, reaching 14.34 B USD. Earnings per share have grown at 15.6% per year over the last 13 years. For Regeneron Pharmaceuticals, the net margin of 31.4% is down versus 50.2% a few years ago. At today's price the dividend yield works out to roughly 0.47%. The payout ratio is around 8% of earnings. The consensus 12-month price target for Regeneron Pharmaceuticals is 800.00 USD, about 5.8% above where the stock trades today. Of 38 analysts, 26 rate the stock a buy — an overall Buy consensus.
Regeneron Pharmaceuticals stock price
Regeneron Pharmaceuticals business model & stock analysis
Frequently asked questions about Regeneron Pharmaceuticals
The business model of Regeneron Pharmaceuticals Inc. revolves around the research, development, and commercialization of innovative biopharmaceutical products. Regeneron focuses on discovering, designing, and manufacturing novel medicines that address unmet medical needs. The company employs advanced technologies, including monoclonal antibody platforms and genetically modified mice, to develop therapies across various therapeutic areas, such as ophthalmology, oncology, and inflammatory diseases. By continuously investing in research and strategic collaborations, Regeneron strives to deliver life-changing treatments, improve patient outcomes, and become a leading force in the biopharmaceutical industry. Visit our website for more information about Regeneron Pharmaceuticals Inc. and its business model.
Regeneron Pharmaceuticals Inc is primarily active in the biopharmaceutical industry.
The main competitors of Regeneron Pharmaceuticals Inc in the market include major pharmaceutical companies like Roche Holding AG, Amgen Inc, and Pfizer Inc. These companies are also involved in the development and commercialization of biopharmaceutical products, competing within the same therapeutic areas as Regeneron.
Regeneron Pharmaceuticals Inc, founded in 1988, is a renowned American biotechnology company specializing in the discovery, development, and commercialization of innovative medicines. Headquartered in Tarrytown, New York, Regeneron has a rich history of pioneering scientific breakthroughs. The company's success can be attributed to its robust research and development initiatives, focusing on various therapeutic areas such as oncology, ophthalmology, cardiovascular diseases, and rare genetic disorders. Regeneron's remarkable achievements include the development of EYLEA® (a leading treatment for retinal diseases) and the groundbreaking antibody cocktail, REGN-COV2, used for COVID-19 treatment. Renowned for its dedication to rigorous scientific research, Regeneron Pharmaceuticals Inc has established itself as a leader in the biopharmaceutical industry.
Regeneron Pharmaceuticals Inc. has achieved several significant milestones since its inception. Notably, the company received FDA approval for its groundbreaking drug, EYLEA®, in 2011, which revolutionized the treatment of age-related macular degeneration. Regeneron also gained recognition for the development of its therapy, Dupixent®, for atopic dermatitis, asthma, and other allergic conditions. In addition, the company has made significant advancements in the field of immuno-oncology with its innovative drug, Libtayo®, approved for the treatment of certain types of skin and lung cancers. Regeneron continues to drive progress in the biopharmaceutical industry by focusing on novel research and development initiatives.
Regeneron Pharmaceuticals Inc primarily operates in various countries and regions around the world. The company has a global presence with key markets in the United States, Europe, and other international locations. Through its strong partnerships and collaborations, Regeneron has expanded its reach and established a significant presence in the biopharmaceutical industry. With its dedication to scientific innovation and breakthrough treatments, Regeneron Pharmaceuticals Inc continues to make a meaningful impact on patients' lives worldwide.
Regeneron Pharmaceuticals Inc is a leading biotechnology company that values innovation, integrity, and collaboration. With a corporate philosophy centered around science-driven discoveries and patient-focused solutions, Regeneron aims to improve lives through its research and development of therapeutic products. They prioritize the use of cutting-edge technologies to address unmet medical needs and strive to deliver impactful medicines to patients worldwide. Regeneron's commitment to transparency, ethical practices, and scientific excellence has established its reputation as a trusted and reliable healthcare partner.
Analysts currently set an average price target of 820.65 USD for the Regeneron Pharmaceuticals stock (median: 800.00 USD), implying +8.5 % versus the latest price. The consensus is based on 38 analyst ratings.
38 analysts currently rate the Regeneron Pharmaceuticals stock: 26 recommend buying, 12 holding and 0 selling. For 2026, analysts expect Regeneron Pharmaceuticals to generate revenue of 17.17 B USD and earnings per share of 55.01 USD.
Converted at the current exchange rate, the Regeneron Pharmaceuticals share trades at 675.58 EUR (756.17 USD).
The Regeneron Pharmaceuticals share (REGN) is listed on 11 stock exchanges, including: NASDAQ (REGN), London (0R2M.L), SIX (Zürich) (RGO.SW), XETRA (RGO.DE), Frankfurt (RGO.F), München (RGO.MU), Düsseldorf (RGO.DU), Hamburg (RGO.HM).
Regeneron Pharmaceuticals is a biotechnology company based in the United States that focuses on researching, developing, and marketing medications. It was founded in 1988 by Leonard Schleifer and George Yancopoulos and is headquartered in Tarrytown, New York. Regeneron is divided into various business divisions that address different medical conditions. This includes the field of ophthalmology, where Regeneron has developed the medication Eylea®, an effective treatment for age-related macular degeneration and other eye diseases. The sales in this area amounted to approximately $7.7 billion in 2020. Another important area is oncology, where Regeneron has developed the cancer medication Libtayo®, which is used to treat skin cancer and lung cancer. The sales in this area amounted to approximately $340 million in 2020. Regeneron is also involved in inflammation diseases, genetic diseases, and infectious diseases. The company has several promising medications in development in these areas, including a treatment for COVID-19. Regeneron collaborates closely with various partners in the pharmaceutical and biotech industry. This includes the British pharmaceutical company Sanofi, with whom Regeneron has already brought several successful medications to the market. The company also has partnerships with other major industry players such as Bayer and Roche. Regeneron places great emphasis on research and development and invests a significant amount of money in this area. In 2020, the R&D expenditure amounted to approximately $3.7 billion, which is about 40 percent of the total revenue. The company employs a large number of scientists and researchers who are constantly working on new medications. Regeneron also values the promotion of young talent. The company has established an extensive scholarship program specifically targeted at students and young scientists. This ensures that highly qualified professionals will be available in the future to further advance the company. In summary, Regeneron's business model specializes in research and development of new medications. The company works closely with various partners and has already brought several promising medications to the market. Regeneron places great importance on promoting young talent and building a highly qualified team of scientists and researchers. Regeneron Pharmaceuticals is a US biotechnology company that specializes in the research, development, and marketing of medications. The company was founded in 1988 by Leonard Schleifer and George Yancopoulos and is headquartered in Tarrytown, New York. Regeneron is divided into several business areas that deal with different medical conditions. This includes the field of ophthalmology, in which Regeneron has developed the effective drug Eylea® for age-related macular degeneration and other eye diseases. Sales in this area were around $7.7 billion in 2020. Another important area is oncology, in which Regeneron has developed the cancer drug Libtayo®, which is used to treat skin cancer and lung cancer. Sales in this area were around $340 million in 2020. Other business areas of Regeneron include inflammatory diseases, genetic diseases, and infectious diseases. In these areas, the company has already developed several promising drugs, including a treatment for COVID-19. Regeneron works closely with various partners in the pharmaceutical and biotech industry. This includes the British pharmaceutical company Sanofi, with which Regeneron has already successfully launched several drugs on the market. The company also has partnerships with other major industry players such as Bayer and Roche. Regeneron places great emphasis on research and development and invests a significant amount of money in this area. In 2020, R&D spending was around $3.7 billion, approximately 40 percent of total revenue. The company employs a large number of scientists and researchers who are constantly working on new drugs. Regeneron also places great importance on promoting young talent. The company has launched an extensive scholarship program specifically targeting students and young scientists. This is to ensure that highly qualified professionals are available in the future to further advance the company. In conclusion, Regeneron's business model specializes in the research and development of new medications. The company works closely with various partners and has already launched several promising drugs on the market. Regeneron places great importance on promoting young talent and building a highly qualified team of scientists and researchers.
The expected revenue of Regeneron Pharmaceuticals is 17.17 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Regeneron Pharmaceuticals is 5.91 B USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Regeneron Pharmaceuticals is currently 13.75. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Regeneron Pharmaceuticals stock.
The price-to-sales ratio (P/S) of Regeneron Pharmaceuticals is currently 4.73. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Regeneron Pharmaceuticals stock.
The Eulerpool Quality Score for Regeneron Pharmaceuticals is 6/10.
The ISIN of Regeneron Pharmaceuticals is US75886F1075. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Regeneron Pharmaceuticals is 881535. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Regeneron Pharmaceuticals is REGN. The ticker symbol is used to trade Regeneron Pharmaceuticals shares on the stock exchange.
Regeneron Pharmaceuticals stock
Regeneron Pharmaceuticals Peer Group
Regeneron Pharmaceuticals Ticker
Regeneron Pharmaceuticals FIGI
All fundamentals and in-depth analysis of Regeneron Pharmaceuticals
Our stock analysis for Regeneron Pharmaceuticals stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Regeneron Pharmaceuticals. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.